MDR1 expression serves as a pharmacogenetic marker for the prediction of molecular, cytogenetic and clinical outcome on 2nd line nilotinib therapy in imatinib-resistant CML patients

被引：0
|
作者：
Agrawal, M. [1 ]
Erben, P. [1 ]
Hanfstein, B. [1 ]
Popa, J. [1 ]
Hofmann, W. K. [1 ]
Leitner, A. [1 ]
Hochhaus, A. [1 ]
Mueller, M. C. [1 ]
机构：
[1] Univ Heidelberg, Mannheim Med Fac, Med Klin 3, D-6900 Heidelberg, Germany
来源：
EUROPEAN JOURNAL OF MEDICAL RESEARCH | 2010年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：86 / 86
页数：1
相关论文
共 14 条
  • [1] MDR1 expression serves as a pharmacogenetic marker for the prediction of molecular, cytogenetic and clinical outcome on 2nd line nilotinib therapy in imatinib-resistant CML patients
    Agrawal, M.
    Erben, P.
    Hanfstein, B.
    Popa, J.
    Hofmann, W-K
    Leitner, A.
    Hochhaus, A.
    Mueller, M. C.
    ONKOLOGIE, 2010, 33 : 144 - 144
  • [2] THE PREDICTIVE IMPACT OF MDR1 EXPRESSION AND PRE-TUMOR BURDEN ON MOLECULAR, CYTOGENETIC AND CLINICAL OUTCOME OF CML PATIENTS ON NILOTINIB THERAPY AFTER IMATINIB FAILURE
    Agrawal, M.
    Erben, P.
    Hanfstein, B.
    Popa, J.
    Hofmann, W. K.
    Reynolds, J.
    Robin, L.
    Leitner, A.
    Woodman, R.
    Hochhaus, A.
    Muller, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 58 - 59
  • [3] MDRI gene expression as pharmacogenetic marker to predict response and progression-free survival on 2nd line nilotinib therapy in imatinib-resistant CML-4-year follow-up.
    Agrawal, M.
    Hanfstein, B.
    Erben, P.
    Saussele, S.
    Hehlmann, R.
    Fabarius, A.
    Hofmann, W-K
    Hochhaus, A.
    Mueller, M. C.
    ONKOLOGIE, 2013, 36 : 99 - 99
  • [4] MDR1 expression predicts outcome of Ph plus chronic phase CML patients on second-line nilotinib therapy after imatinib failure
    Agrawal, M.
    Hanfstein, B.
    Erben, P.
    Wolf, D.
    Ernst, T.
    Fabarius, A.
    Saussele, S.
    Purkayastha, D.
    Woodman, R. C.
    Hofmann, W-K
    Hehlmann, R.
    Hochhaus, A.
    Mueller, M. C.
    LEUKEMIA, 2014, 28 (07) : 1478 - 1485
  • [5] MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure
    M Agrawal
    B Hanfstein
    P Erben
    D Wolf
    T Ernst
    A Fabarius
    S Saussele
    D Purkayastha
    R C Woodman
    W-K Hofmann
    R Hehlmann
    A Hochhaus
    M C Müller
    Leukemia, 2014, 28 : 1478 - 1485
  • [6] MDR-1 expression predicts molecular response in CML patients on nilotinib therapy after imatinib failure
    Agrawal, M.
    Erben, Philipp
    Mueller, Martin Christian
    Daikeler, Hannah
    Schenk, Thomas
    Hanfstein, Benjamin
    Hochhaus, Andreas
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2009, 14 : 41 - 41
  • [7] MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure.
    Agrawal, Mridul
    Erben, Philipp
    Hanfstein, Benjamin
    Daikeler, Hannah
    Popa, Juliana
    Schenk, Thomas
    Leitner, Armin
    Woodman, Richard C.
    Hochhaus, Andreas
    Mueller, Martin C.
    BLOOD, 2009, 114 (22) : 1026 - 1026
  • [8] The expression of MDR1 makes it possible to predict the prognosis of patients in chronic phase of CML in failure of imatinib treatment submitted in the second line to nilotinib
    Costello, Regis
    HEMATOLOGIE, 2014, 20 (02): : 90 - 92
  • [9] Expression levels of MDR1 and OCT-1 predict molecular responses in chronic phase CML patients on first line imatinib treatment
    Erben, P.
    Daikeler, H.
    Hanfstein, B.
    Agrawal, M.
    Popa, J.
    Nowak, D.
    Munjal, U.
    Leitner, A.
    Saussele, S.
    Hofmann, W-K
    Hehlmann, R.
    Hochhaus, A.
    Mueller, M-C
    ONKOLOGIE, 2010, 33 : 144 - 145
  • [10] MDR1 Gene Expression Predicts Response and Progression-Free Survival Of Ph plus CML Patients On Second-Line Nilotinib Therapy After Imatinib Failure-4-Year Follow-Up
    Agrawal, Mridul
    Hanfstein, Benjamin
    Erben, Philipp
    Wolf, Dominik
    Ernst, Thomas
    Saussele, Susanne
    Fabarius, Alice
    Purkayasatha, Das
    Woodman, Richard C.
    Hehlmann, Ruediger
    Hofmann, Wolf-Karsten
    Hochhaus, Andreas
    Mueller, Martin C.
    BLOOD, 2013, 122 (21)
12